Diabetes
Explore published findings of medical trials and real-world evidence.
This page includes links to Novo Nordisk-sponsored trials and observational research published in peer reviewed journals. The list of publications below is sorted by product and limited to products that have been approved for use. Please note that publications may contain information about doses, delivery devices, uses, formulations and/or populations that differs from FDA-required labeling. Novo Nordisk does not suggest or recommend the use of its products in any manner other than as described in their FDA-required labeling, which is findable under each product below.
Products are listed in order of the most recent FDA approval, with the most recent shown first.
Ozempic® (semaglutide) tablets 4 mg or 9 mg, Rybelsus® (semaglutide) tablets 7 mg or 14 mg | Full Prescribing Information
Published Date: December 2019
(semaglutide) injection 0.5 mg, 1 mg, 2 mg | Full Prescribing Information
Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): A randomized, controlled trial.
Published Date: June 1 2018
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN 6).
Published Date: November 10, 2016
Published Date: February 2025
Glucose-lowering treatment patterns in patients with diabetic kidney disease.
Published Date: August 1, 2022
(icodec-abae) injection 700U/mL | Full Prescribing Information
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin
Published Date: June 2023
Published Date: February 2025
Published Date: October 2022
Disease Education
Congress materials
Find product information
Explore our portfolio of products, including prescribing information, safety data sheets, and storage and stability information.
Continuing education
Learn about accredited disease education opportunities supported by Novo Nordisk and provided by third-party organizations.